Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX OTCMKTS:CXRXF NASDAQ:EOLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$4.00-3.1%$4.66$0.91▼$8.21$680.76M2.185.79 million shs3.10 million shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsEOLSEvolus$6.39+1.1%$4.76$3.86▼$11.42$420.85M1.281.21 million shs938,433 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics+1.23%+1.98%-6.14%-21.18%+324.02%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%EOLSEvolus-0.78%+22.01%+51.92%+43.31%-45.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$4.00-3.1%$4.66$0.91▼$8.21$680.76M2.185.79 million shs3.10 million shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsEOLSEvolus$6.39+1.1%$4.76$3.86▼$11.42$420.85M1.281.21 million shs938,433 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics+1.23%+1.98%-6.14%-21.18%+324.02%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%EOLSEvolus-0.78%+22.01%+51.92%+43.31%-45.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.80Moderate Buy$13.44236.11% UpsideCXRXFADVANZ PHARMA 0.00N/AN/AN/AEOLSEvolus 2.50Moderate Buy$16.00150.39% UpsideCurrent Analyst Ratings BreakdownLatest EOLS, CTMX, and CXRXF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)3/23/2026CTMXCytomX Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $12.003/19/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)3/19/2026CTMXCytomX Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $16.003/18/2026CTMXCytomX Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $16.003/18/2026CTMXCytomX Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $15.003/17/2026CTMXCytomX Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $11.003/16/2026CTMXCytomX Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.003/16/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $17.003/16/2026CTMXCytomX Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$7.00 ➝ $12.003/9/2026CTMXCytomX Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$76.20M8.93N/AN/A$0.58 per share6.90CXRXFADVANZ PHARMA$525.58M1.59N/AN/A$0.16 per share106.63EOLSEvolus$297.18M1.42N/AN/A($0.44) per share-14.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$17.37M-$0.04N/AN/AN/A-22.79%-19.77%-11.91%5/7/2026 (Estimated)CXRXFADVANZ PHARMA-$74.86MN/AN/AN/AN/A-15.31%N/A-4.38%N/AEOLSEvolus-$51.64M-$0.81N/A127.80N/A-14.39%N/A-19.03%N/ALatest EOLS, CTMX, and CXRXF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/4/2026Q1 2026EOLSEvolus-$0.14-$0.16-$0.02-$0.16$72.52 million$73.14 million3/16/2026Q4 2025CTMXCytomX Therapeutics-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 million3/3/2026Q4 2025EOLSEvolus$0.09$0.0020-$0.0880N/A$89.58 million$90.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A3.093.09CXRXFADVANZ PHARMA257.042.391.61EOLSEvolusN/A2.041.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%CXRXFADVANZ PHARMAN/AEOLSEvolus90.69%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%CXRXFADVANZ PHARMAN/AEOLSEvolus5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170170.19 million158.96 millionOptionableCXRXFADVANZ PHARMA42948.91 millionN/ANot OptionableEOLSEvolus17065.86 million61.97 millionOptionableEOLS, CTMX, and CXRXF HeadlinesRecent News About These CompaniesEvolus Ends ATM Facility After Strong Q1 MomentumMay 6 at 9:53 AM | theglobeandmail.comBTIG Sticks to Their Buy Rating for Evolus (EOLS)May 6 at 9:53 AM | theglobeandmail.comEvolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery GapsMay 6 at 2:11 AM | tipranks.comEvolus, Inc. (EOLS) Q1 2026 Earnings Call TranscriptMay 5 at 3:01 AM | seekingalpha.comEvolus Earnings Call Highlights Profitable Growth PathMay 4 at 8:31 PM | tipranks.comEvolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue EstimatesMay 4 at 8:30 PM | zacks.comEvolus Posts Mixed Q1 ResultsMay 4 at 7:12 PM | ocbj.comOEvolus (EOLS) Q2 2025 Earnings Call TranscriptMay 4 at 7:12 PM | finance.yahoo.comEvolus (EOLS) Q1 2026 Earnings TranscriptMay 4 at 7:12 PM | finance.yahoo.comEvolus Q1 Earnings Call HighlightsMay 4 at 6:16 PM | marketbeat.comEvolus (NASDAQ:EOLS) Releases Earnings Results, Misses Expectations By $0.02 EPSMay 4 at 4:25 PM | marketbeat.comEvolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year OutlookMay 4 at 4:05 PM | businesswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Evolus (EOLS) and Bausch Health Companies (BHC)May 2, 2026 | theglobeandmail.comEvolus Q1 2026 earnings previewMay 2, 2026 | msn.comEvolus (EOLS) to Release Quarterly Earnings on MondayApril 27, 2026 | marketbeat.comHow The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation AssumptionsApril 26, 2026 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of "Moderate Buy" by AnalystsApril 21, 2026 | marketbeat.comShort Interest in Evolus, Inc. (NASDAQ:EOLS) Drops By 14.4%April 17, 2026 | marketbeat.comEvolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare ConferenceApril 15, 2026 | marketbeat.comEvolus to Report First Quarter Financial Results on May 4, 2026April 14, 2026 | businesswire.comHow The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target CutsApril 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEOLS, CTMX, and CXRXF Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$4.00 -0.13 (-3.15%) Closing price 04:00 PM EasternExtended Trading$4.00 0.00 (-0.12%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.ADVANZ PHARMA OTCMKTS:CXRXF$17.06 0.00 (0.00%) As of 06/10/2021ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.Evolus NASDAQ:EOLS$6.39 +0.07 (+1.11%) Closing price 04:00 PM EasternExtended Trading$6.36 -0.03 (-0.49%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
